Display options
Cite
Song H, Xi S, Chen Y, et al. Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation. Cancer Lett. 2021;520:201-212doi: 10.1016/j.canlet.2021.07.020.
Song, H., Xi, S., Chen, Y., Pramanik, S., Zeng, J., Roychoudhury, S., Harris, H., Akbar, A., Elhag, S. S., Coulter, D. W., Ray, S., & Bhakat, K. K. (2021). Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation. Cancer letters, 520201-212. https://doi.org/10.1016/j.canlet.2021.07.020
Song, Heyu, et al. "Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation." Cancer letters vol. 520 (2021): 201-212. doi: https://doi.org/10.1016/j.canlet.2021.07.020
Song H, Xi S, Chen Y, Pramanik S, Zeng J, Roychoudhury S, Harris H, Akbar A, Elhag SS, Coulter DW, Ray S, Bhakat KK. Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation. Cancer Lett. 2021 Nov 01;520:201-212. doi: 10.1016/j.canlet.2021.07.020. Epub 2021 Jul 14. PMID: 34271103; PMCID: PMC8440470.
Copy Download .nbib Format: NLM
Share it on

Cancer Lett. 2021 Nov 01;520:201-212. doi: 10.1016/j.canlet.2021.07.020. Epub 2021 Jul 14.

Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation.

Cancer letters

Heyu Song, Shaoyan Xi, Yingling Chen, Suravi Pramanik, Jiping Zeng, Shrabasti Roychoudhury, Hannah Harris, Anum Akbar, Salma S Elhag, Donald W Coulter, Sutapa Ray, Kishor K Bhakat

Affiliations

  1. Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  2. Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
  3. Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  4. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  5. Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
  6. Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: [email protected].
  7. Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: [email protected].

PMID: 34271103 PMCID: PMC8440470 DOI: 10.1016/j.canlet.2021.07.020

Abstract

Medulloblastoma (MB) is a malignant pediatric brain tumor with a poor prognosis. Post-surgical radiation and cisplatin-based chemotherapy have been a mainstay of treatment, which often leads to substantial neurocognitive impairments and morbidity, highlighting the need for a novel therapeutic target to enhance the sensitivity of MB tumors to cytotoxic therapies. We performed a comprehensive study using a cohort of 71 MB patients' samples and pediatric MB cell lines and found that MB tumors have elevated levels of nucleosome remodeling FACT (FAcilitates Chromatin Transcription) complex and DNA repair enzyme AP-endonuclease1 (APE1). FACT interacts with APE1 and facilitates recruitment and acetylation of APE1 to promote repair of radiation and cisplatin-induced DNA damage. Further, levels of FACT and acetylated APE1 both are correlate strongly with MB patients' survival. Targeting FACT complex with CBL0137 inhibits DNA repair and alters expression of a subset of genes, and significantly improves the potency of cisplatin and radiation in vitro and in MB xenograft. Notably, combination of CBL0137 and cisplatin significantly suppressed MB tumor growth in an intracranial orthotopic xenograft model. We conclude that FACT complex promotes chemo-radiation resistance in MB, and FACT inhibitor CBL0137 can be used as a chemo-radiation sensitizer to augment treatment efficacy and reduce therapy-related toxicity in high-risk pediatric patients.

Copyright © 2021 Elsevier B.V. All rights reserved.

Keywords: APE1; CBL0137; DNA repair; FACT; Medulloblastoma

References

  1. Cancer Chemother Pharmacol. 2009 Mar;63(4):753-8 - PubMed
  2. Cancer Cell. 2017 Jun 12;31(6):737-754.e6 - PubMed
  3. Nature. 2014 Jan 23;505(7484):564-8 - PubMed
  4. Neuro Oncol. 2017 Feb 1;19(2):186-196 - PubMed
  5. Mol Cancer Ther. 2020 Jan;19(1):258-269 - PubMed
  6. J Biol Chem. 2011 Apr 22;286(16):14564-74 - PubMed
  7. Mol Carcinog. 2018 Apr;57(4):536-548 - PubMed
  8. Oncotarget. 2016 Nov 15;7(46):75197-75209 - PubMed
  9. Acta Neuropathol. 2012 Apr;123(4):465-72 - PubMed
  10. Cold Spring Harb Perspect Med. 2013 Nov 01;3(11): - PubMed
  11. Sci Adv. 2018 Nov 07;4(11):eaav2131 - PubMed
  12. Cell Rep. 2013 Jul 11;4(1):159-73 - PubMed
  13. DNA Repair (Amst). 2015 Dec;36:13-18 - PubMed
  14. DNA Repair (Amst). 2017 Mar;51:46-59 - PubMed
  15. Front Oncol. 2014 Jul 22;4:176 - PubMed
  16. Int J Cancer. 2000 Sep 20;89(5):395-402 - PubMed
  17. Pediatr Blood Cancer. 2017 Apr;64(4): - PubMed
  18. Cancer Treat Rev. 2010 Aug;36(5):425-35 - PubMed
  19. Heliyon. 2021 Apr 16;7(4):e06756 - PubMed
  20. Cell Cycle. 2013 Aug 1;12(15):2423-34 - PubMed
  21. Cancer Res. 2018 Mar 15;78(6):1431-1443 - PubMed
  22. Cancer Res. 2016 Apr 15;76(8):2432-42 - PubMed
  23. Antioxid Redox Signal. 2014 Feb 1;20(4):678-707 - PubMed
  24. Int J Oncol. 2011 May;38(5):1329-41 - PubMed
  25. Nat Protoc. 2012 Mar 01;7(3):562-78 - PubMed
  26. Antioxid Redox Signal. 2011 Apr 15;14(8):1387-401 - PubMed
  27. Chem Rev. 2007 May;107(5):1387-407 - PubMed
  28. Mol Cell Biol. 2017 Mar 1;37(6): - PubMed
  29. Mol Cell. 2013 Aug 22;51(4):469-79 - PubMed
  30. Cancer Cell. 2018 Mar 12;33(3):435-449.e6 - PubMed
  31. Cancer Res. 2017 May 15;77(10):2674-2685 - PubMed
  32. Cell Res. 2008 Jan;18(1):27-47 - PubMed
  33. Genetics. 2002 Dec;162(4):1557-71 - PubMed
  34. Mol Cell Biol. 2008 Dec;28(23):7066-80 - PubMed
  35. J Biol Chem. 2011 May 27;286(21):18369-74 - PubMed
  36. EMBO J. 2009 Apr 8;28(7):854-65 - PubMed
  37. PLoS Genet. 2016 Jul 28;12(7):e1006221 - PubMed
  38. J Clin Oncol. 2019 Mar 20;37(9):731-740 - PubMed
  39. Science. 2003 Aug 22;301(5636):1090-3 - PubMed
  40. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53 - PubMed
  41. Cancer Res. 2010 Jan 1;70(1):181-91 - PubMed
  42. Cancer Res. 2018 May 1;78(9):2396-2406 - PubMed
  43. Sci Transl Med. 2011 Aug 10;3(95):95ra74 - PubMed
  44. Biochem Biophys Res Commun. 2019 Dec 3;520(2):250-256 - PubMed
  45. Cell Death Dis. 2020 Dec 2;11(12):1029 - PubMed
  46. Sci Transl Med. 2015 Nov 4;7(312):312ra176 - PubMed
  47. Clin Cancer Res. 2005 Oct 15;11(20):7405-14 - PubMed
  48. Oncogene. 2011 Jan 27;30(4):482-93 - PubMed

Publication Types

Grant support